chartexchange

BioNTech SE (BNTX) (Q3 2026) Earnings Call Highlights: Oncology Pipeline Momentum Builds as ...

GuruFocus | Nov 3, 2026 10:04 PM EST

BioNTech SE (BNTX) reaffirmed full-year 2026 guidance while spotlighting strong Gotistobart and Pumitamig data, a EUR 16.2 billion cash position, and mixed mRNA cancer vaccine results. Related Stocks: BNTX ,

Read original article